Indeed, the immune response was experienced in Kovid-19 patients, whose immune system released a large amount of protein and promoted inflammation. The purpose of this clinical trial is to determine whether the immune response can reduce the need for ventilators and reduce patients’ hospital stay.
According to the Xinhua report, a trial named Active-1 Immune Modulator will determine whether the therapy can balance the highly active immune system.
The trial is expected to be conducted on approximately 2,100 patients admitted to Kovid hospitals in the United States and Latin America.
A placebo or immune modulator was given to those involved in the trial. According to the NIH, one will study different types of combinations in relation to disease severity, speed of recovery, mortality, and resource utilization of hospitals.